What changed
$PFE — ADD 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $14.5B | EPS $0.75 vs $0.72 🟢
💡 Consensus expects flat earnings and no multiple expansion. Variant view: management's cost cutting and newer product launches will sustain earnings above consensus, while the market underappreciates the dividend yield's cushion, making the stock attractive at lower prices.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 6/10
📊 Valuation: fair - At 19.6x trailing earnings, PFE trades at median of its 5-year range and in line with large-cap pharma peers; requires earnings growth to...
🔮 Catalyst: Next quarterly earnings report
💰 Entry: $23.0, stop $21.0, target $27.0
⚖️ Add Pfizer on pullback to $23 for a 2:1 risk/reward, capitalizing on cost efficiency and yield; current price lacks margin of safety.
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/PFE0623